​

Oruka Therapeutics Stock (NASDAQ:ORKA)

ForecastOwnershipFinancialsChart
Oruka Therapeutics by TradingView

Previous Close

$27.70

52W Range

$5.49 - $30.40

50D Avg

$19.11

200D Avg

$13.57

Market Cap

$1.03B

Avg Vol (3M)

$346.36K

Beta

-0.33

Div Yield

$19.36

ORKA Company Profile

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

28

IPO Date

-

Website

ORKA Performance

ORKA Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-88.12M$-7.30M$-9.84M
Net Income$-83.72M$-5.34M$-9.93M
EBITDA$-82.23M$-5.23M$-9.81M
Basic EPS$-4.99$-4.44$-8.27
Diluted EPS$-4.99$-4.44$-8.27

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
INVAInnoviva, Inc.
TNGXTango Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
SEPNSepterna, Inc.
SPRYARS Pharmaceuticals, Inc.
BCAXBicara Therapeutics Inc. Common Stock
MDXGMiMedx Group, Inc.
PGENPrecigen, Inc.
PROKProKidney Corp.
MNMDMind Medicine (MindMed) Inc.